Brainomix has secured investment from the University of Oxford Isis Fund I and Parkwalk Funds to enhance stroke treatment through its innovative e-ASPECTS software, aimed at improving diagnostic accuracy in hospitals and clinics.

Information on the Target

Brainomix is a pioneering company focused on revolutionizing stroke treatment through advanced software solutions. The company aims to provide hospitals and clinics with reliable diagnostic tools, facilitating timely treatment for stroke patients. Strokes are a leading cause of death and the primary contributor to disability worldwide, with a significant number of patients not receiving necessary care due to challenges in interpreting CT scan images accurately.

Co-founded by Professor Alastair Buchan, Brainomix has introduced the e-ASPECTS software, which enables automated and standardized analysis of CT brain scans. This innovation addresses the limitations of traditional diagnostic methods and enhances the ability of healthcare professionals to make informed treatment decisions regarding stroke damage and patient suitability for life-saving interventions.

Industry Overview in the Target's Specific Country

The healthcare industry, particularly stroke treatment, operates within a complex landscape, influenced by factors such as demographic changes, technological advancements, and evolving patient n